Serum YKL-40 concentrations in newly diagnosed multiple myeloma patients and YKL-40 expression in malignant plasma cells
(2006) In European Journal of Haematology 77(5). p.416-424- Abstract
- Objectives: A potential role in cancer biology is suggested for YKL-40 (CHI3L1, HC gp-39). The purpose of this study was to evaluate the clinical value of serum YKL-40 (sYKL-40) in multiple myeloma (MM) and to examine YKL-40 expression in malignant plasma cells (MM PCs). Methods: sYKL-40 was measured by enzyme-linked immunosorbent assay (ELISA) in 82 patients with newly diagnosed MM. YKL-40 expression in immunophenotypically defined plasma cells was investigated by double-labelled immunohistochemistry in 21 MM patients and by real-time reverse transcriptase polymerase chain reaction (RT-PCR) in cDNA archives generated by global RT-PCR in seven controls, 14 patients with monoclonal gammopathy of undetermined significance (MGUS), 45 MM... (More)
- Objectives: A potential role in cancer biology is suggested for YKL-40 (CHI3L1, HC gp-39). The purpose of this study was to evaluate the clinical value of serum YKL-40 (sYKL-40) in multiple myeloma (MM) and to examine YKL-40 expression in malignant plasma cells (MM PCs). Methods: sYKL-40 was measured by enzyme-linked immunosorbent assay (ELISA) in 82 patients with newly diagnosed MM. YKL-40 expression in immunophenotypically defined plasma cells was investigated by double-labelled immunohistochemistry in 21 MM patients and by real-time reverse transcriptase polymerase chain reaction (RT-PCR) in cDNA archives generated by global RT-PCR in seven controls, 14 patients with monoclonal gammopathy of undetermined significance (MGUS), 45 MM patients, nine patients with extramedullary myeloma (exMM), and seven human myeloma cell lines (HMCLs). Results: sYKL-40 was elevated above a constructed reference range for healthy controls in 29% of the patients investigated. Patients with elevated sYKL-40 had reduced overall survival and event-free survival when compared to patients with normal sYKL-40, but sYKL-40 level was defeated by beta(2)-microglobulin in the multivariate analyses. Intramedullary MM PCs lacked significant expression of YKL-40, but high levels of YKL-40 expression were seen in extramedullary MM PCs from one exMM patient and in six HMCLs. Further investigations of other bone marrow (BM) cells showed YKL-40 expression in megakaryocytes, neutrophils and adherent cells from long-term BM cultures. Conclusions: In newly diagnosed MM-patients, a sYKL-40 elevated above the reference range predicts a poor clinical outcome, and YKL-40 is expressed by other BM cells than MM PCs. At this point, routine measurements of sYKL-40 are not warranted, but YKL-40 should be considered as a potential player in the pathophysiology of MM. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/392759
- author
- Mylin, Anne K. ; Rasmussen, Thomas ; Johansen, Julia S. ; Knudsen, Lene M. ; Norgaard, Peter H. ; Lenhoff, Stig LU ; Dahl, Inger M. S. and Johnsen, Hans E.
- organization
- publishing date
- 2006
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- human cartilage, chitinase 3-like 1, multiple myeloma, YKL-40, glycoprotein-39
- in
- European Journal of Haematology
- volume
- 77
- issue
- 5
- pages
- 416 - 424
- publisher
- Wiley-Blackwell
- external identifiers
-
- wos:000240834300008
- scopus:33749240157
- pmid:16930142
- ISSN
- 1600-0609
- DOI
- 10.1111/j.0902-4441.2006.t01-1-EJH2879.x
- language
- English
- LU publication?
- yes
- id
- 1ee752a7-9799-4dd7-a331-627460637acb (old id 392759)
- date added to LUP
- 2016-04-01 12:22:15
- date last changed
- 2022-01-27 02:48:42
@article{1ee752a7-9799-4dd7-a331-627460637acb,
abstract = {{Objectives: A potential role in cancer biology is suggested for YKL-40 (CHI3L1, HC gp-39). The purpose of this study was to evaluate the clinical value of serum YKL-40 (sYKL-40) in multiple myeloma (MM) and to examine YKL-40 expression in malignant plasma cells (MM PCs). Methods: sYKL-40 was measured by enzyme-linked immunosorbent assay (ELISA) in 82 patients with newly diagnosed MM. YKL-40 expression in immunophenotypically defined plasma cells was investigated by double-labelled immunohistochemistry in 21 MM patients and by real-time reverse transcriptase polymerase chain reaction (RT-PCR) in cDNA archives generated by global RT-PCR in seven controls, 14 patients with monoclonal gammopathy of undetermined significance (MGUS), 45 MM patients, nine patients with extramedullary myeloma (exMM), and seven human myeloma cell lines (HMCLs). Results: sYKL-40 was elevated above a constructed reference range for healthy controls in 29% of the patients investigated. Patients with elevated sYKL-40 had reduced overall survival and event-free survival when compared to patients with normal sYKL-40, but sYKL-40 level was defeated by beta(2)-microglobulin in the multivariate analyses. Intramedullary MM PCs lacked significant expression of YKL-40, but high levels of YKL-40 expression were seen in extramedullary MM PCs from one exMM patient and in six HMCLs. Further investigations of other bone marrow (BM) cells showed YKL-40 expression in megakaryocytes, neutrophils and adherent cells from long-term BM cultures. Conclusions: In newly diagnosed MM-patients, a sYKL-40 elevated above the reference range predicts a poor clinical outcome, and YKL-40 is expressed by other BM cells than MM PCs. At this point, routine measurements of sYKL-40 are not warranted, but YKL-40 should be considered as a potential player in the pathophysiology of MM.}},
author = {{Mylin, Anne K. and Rasmussen, Thomas and Johansen, Julia S. and Knudsen, Lene M. and Norgaard, Peter H. and Lenhoff, Stig and Dahl, Inger M. S. and Johnsen, Hans E.}},
issn = {{1600-0609}},
keywords = {{human cartilage; chitinase 3-like 1; multiple myeloma; YKL-40; glycoprotein-39}},
language = {{eng}},
number = {{5}},
pages = {{416--424}},
publisher = {{Wiley-Blackwell}},
series = {{European Journal of Haematology}},
title = {{Serum YKL-40 concentrations in newly diagnosed multiple myeloma patients and YKL-40 expression in malignant plasma cells}},
url = {{http://dx.doi.org/10.1111/j.0902-4441.2006.t01-1-EJH2879.x}},
doi = {{10.1111/j.0902-4441.2006.t01-1-EJH2879.x}},
volume = {{77}},
year = {{2006}},
}